Vinci Pharmaceuticals, Inc., a specialty ophthalmic company aiming to disrupt the treatment of retinal diseases with novel, next-generation platform technologies, has secured $8.0M in Series A funding. The capital infusion will accelerate the development and refinement of its proprietary solutions.
Central to Vinci's mission is EPIPLANTā¢, a transformative platform technology designed to provide safe, effective, and crucially, needle-free drug delivery directly to the retina. This Series A round positions the company to advance its innovative approach to ophthalmic care, moving beyond traditional, more invasive methods.
